Compare Stocks → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:FTSV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTSVForty Seven0.00%0.00%0.00%0.00%0.00%A letter is coming from the "Bureau of the Fiscal Service". (Ad)Is your bank next? A powerful new trend is spreading like wildfire inside the US financial system. At least 41 banks are already involved. But the Federal Reserve predicts that number will grow fast.See if your bank is involved right here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTSVForty SevenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTSVForty SevenN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTSVForty SevenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTSVForty SevenN/A14.8114.81OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTSVForty Seven71.77%Insider OwnershipCompanyInsider OwnershipFTSVForty Seven37.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFTSVForty Seven5748.16 millionN/ANot OptionableENGI, FTSV, BERM, and SPPC HeadlinesRecent News About These CompaniesMay 2, 2024 | msn.com95.7 The Game hosts warn 49ers' first-round pick not to say 'San Fran'April 28, 2024 | msn.comUSS Forrestal: Triumph and Tragedy of America's First 'Super' Aircraft CarrierApril 27, 2024 | ninerswire.usatoday.comNFL Twitter reacts to 49ers drafting Florida State CB Renardo Green in second roundApril 11, 2024 | fftimes.comStudy Finds DULF Reduced Overdoses by Distributing Tested DrugsApril 9, 2024 | msn.com49ers sign veteran tight endMarch 28, 2024 | msn.comParent Of FTX Victim Who Lost $130K Recommends Six-Year Sentence For Sam Bankman-Fried, Countering DOJ's 40-50 YearsJanuary 30, 2024 | deadline.comFathom Events Sets March Release For ‘Forty-Seven Days With Jesus’December 23, 2023 | en.mercopress.comForty US states filed a lawsuit against pharmaceutical firms colluding oligopolyNovember 16, 2023 | morningstar.comFormula Systems (1985) Ltd ADR FORTYOctober 27, 2023 | nypost.comSix young men found dead, one injured in search for seven abducted Mexican teenagersOctober 10, 2023 | bizjournals.com$18M upgrade makes historic downtown Milwaukee high-rise a modern data centerSeptember 15, 2023 | buffalorising.comForty Thieves Kitchen & BarSeptember 11, 2023 | msn.comTampa radio station 101.5 has changed from Top 40 to R&B formatAugust 28, 2023 | education.comSeven Times Tables PracticeAugust 26, 2023 | zigwheels.comJawa Forty Two SpecificationsAugust 18, 2023 | msn.comJRA Chair: Seven businesses coming to Farish StreetJuly 21, 2023 | ign.comThe Seven HarrysJuly 10, 2023 | en.mercopress.comForty years ago Watergate forced Nixon to became the only US president to resignJuly 9, 2023 | hackaday.comseven segment displayJune 11, 2023 | dailymail.co.ukWeek one: seven-day detoxCompany DescriptionsForty SevenNASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
